Clinical Trials Logo

Filter by:
NCT ID: NCT01500278 Completed - Clinical trials for Rheumatoid Arthritis

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Start date: December 2011
Phase: Phase 4
Study type: Interventional

This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.

NCT ID: NCT01499537 Completed - Jaundice Clinical Trials

Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct

Start date: January 2011
Phase: N/A
Study type: Interventional

At this time, endoscopic retrograde cholangiopancreatography (ERCP) stay the gold standard method to achieve biliary drainage in case of malignant or benign stricture. When ERCP fail or if the major papilla is not suitable, percutaneous transhepatic biliary drainage (PTBD) is the most commonly used alternative, surgery having higher morbidity and mortality rates, unacceptable especially in palliative situation. Recent developments in interventional endoscopic ultrasonography (EUS) allow new endoluminal approaches to pancreatic-biliary structures, such as cysto-enterostomy or pancreatic-enterostomy. More recently were described the possibility to realize EUS-guided biliary drainage, through the duodenal or the gastric wall. Advantages of the EUS-guided approach are to be realizable even the papilla is not suitable endoscopically (duodenal stricture or post-surgical status) and to allow if necessary extra-tumoral non anatomic drainage (hepaticogastrostomy). This technique is actually an alternative to PTBD. In comparison of the PTBD, EUS-guided route seems to have less morbidity and to avoid external biliary drainage. Indeed, the morbidity rate of the percutaneous biliary drainage and the EUS-guided biliary drainage range respectively from 25 to 35% and from 0 to 23%. However, none study compare prospectively both techniques. Aims of this study are to compare the morbidity rate, feasibility and efficacy of these techniques.

NCT ID: NCT01210274 Recruiting - Clinical trials for Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

Characterization of the Mechanisms of Resistance to Azacitidine

Start date: September 2010
Phase: N/A
Study type: Observational

Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. The primary mode of action of Azacytidine is through DNA demethylation, and integration in to mRNA that favor traduction inhibition. The impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known. The research program and clinical studies we proposed focus on two major aspects: - Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of apoptosis versus autophagy. - Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).

NCT ID: NCT01183832 Completed - Breast Cancer Clinical Trials

Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

ORACLES
Start date: August 2005
Phase:
Study type: Observational

This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.

NCT ID: NCT01170611 Completed - Clinical trials for Sinus Node Dysfunction

Prevention of Atrial Arrhythmia in Patients Without Atrioventricular (AV) Conduction Disease

Start date: July 2004
Phase: Phase 4
Study type: Interventional

This clinical investigation is a prospective, single-blinded, randomized trial. The primary objective concerns the safety and effectiveness of the AAIsafeR mode with the preventive algorithms.

NCT ID: NCT01000441 Completed - Clinical trials for Rheumatoid Arthritis

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

ROC
Start date: December 23, 2009
Phase: Phase 4
Study type: Interventional

Approximately 30% of patients with rheumatoid arthritis have an inadequate response to anti-TNF (primarily or loss of response), leaving two alternatives: rotation to a second anti-TNF or change of biologic, with a different mechanism of action, such as abatacept, rituximab and tocilizumab. No controlled trial compared these two strategies face to face. The present objective is to investigate the issue whether one of these strategies could have a better efficacy in a pragmatic trial in the setting of current practice.

NCT ID: NCT00930410 Completed - Bile Duct Diseases Clinical Trials

Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor

EMID
Start date: September 2008
Phase: N/A
Study type: Interventional

The endomicroscopy is an adaptation of traditional optical microscopy in the digestive endoscopy. Furthermore, with the integration of a miniaturized laser confocal microscope to a videoendoscope, it's possible to study the digestive mucous by "optical biopsy". This monocentric, non randomized and prospective study uses the Intra-ductal confocal endomicroscopy for the characterization of pancreas and bile duct tumor.

NCT ID: NCT00913458 Completed - Clinical trials for Rheumatoid Arthritis

Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.

NCT ID: NCT00768053 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients

Rainbow
Start date: October 2008
Phase: Phase 4
Study type: Interventional

The Disease Activity Score (DAS) is a system of measurement developed in the 1980s that uses certain criteria, including joint counts and patient perceived disease activity, to measure disease activity in people with Rheumatoid Arthritis . More recently, the European League against Rheumatism (EULAR) has developed a new system of measurement known as the Rheumatoid Arthritis Impact of Disease score, or EULAR-RAID score. The EULAR-RAID score is a composite score based on patient reported outcomes, and includes such criteria as pain, functional disability, fatigue, sleep disturbances, coping, overall assessment of physical well being and overall assessment of psychological well being. The objective of this study is to evaluate the practical modalities and performance of the EULAR- RAID score in patients with rheumatoid arthritis who have been prescribed etanercept as part of usual medical practice.

NCT ID: NCT00740987 Completed - Clinical trials for No High Risk of Hemorrhage

Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)

CIREA2
Start date: October 2007
Phase: Phase 3
Study type: Interventional

This multicentre open-label randomized parallel-group trial aims to compare the association of intermittent pneumatic compression of the lower limbs + elastic stockings + anticoagulant prophylaxis to anticoagulant prophylaxis alone on the incidence of venous thromboembolism systematically evaluated at day 6, in patients hospitalized in intensive care units and without high bleeding risk.